PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerviewpress.com

subscribe
share






Cedric "Jamie" Rutland, MD - An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy


Go online to PeerView.com/QXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung disease discusses the diagnosis of and novel and emerging therapies to treat chronic fibrosing interstitial lung disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize risk factors associated with the development of chronic fibrosing interstitial lung disease (CF-ILD), such as having a connective tissue disease, chronic hypersensitivity pneumonitis, and unclassifiable ILD, Identify signs and symptoms indicative of CF-ILD to allow for earlier diagnosis, pulmonary monitoring, and treatment, Discuss the latest clinical data on efficacy and safety for novel and emerging therapies to treat CF-ILD, Develop individualized treatment plans for patients with CF-ILD based on the latest expert recommendations and clinical evidence.


fyyd: Podcast Search Engine
share








 June 24, 2021  33m